406 | Animals |
372 | Humans |
192 | Influenza A virus (immunology) |
157 | Mice |
157 | Influenza A virus (genetics) |
122 | Female |
121 | Influenza Vaccines (immunology) |
91 | Influenza, Human (virology) |
89 | Influenza, Human (epidemiology) |
89 | Influenza A Virus, H2N2 Subtype |
81 | Influenza, Human (prevention & control) |
78 | Adult |
73 | Mice, Inbred BALB C |
72 | Influenza |
69 | Influenza A Virus, H2N2 Subtype (immunology) |
68 | Male |
68 | Influenza, Human (immunology) |
63 | Molecular Sequence Data |
62 | Virus Replication |
62 | Influenza Vaccines (administration & dosage) |
62 | Cold Temperature |
62 | Child |
62 | Adolescent |
59 | Mutation |
59 | Chick Embryo |
58 | Influenza A Virus, H2N2 Subtype (genetics) |
56 | Influenza A virus |
56 | Influenza A virus (pathogenicity) |
55 | Vaccines, Attenuated (immunology) |
55 | Recombination, Genetic |
54 | Hemagglutination Inhibition Tests |
51 | Middle Aged |
50 | Viral Proteins (genetics) |
50 | Orthomyxoviridae Infections (immunology) |
50 | Genes, Viral |
50 | Cell Line |
50 | Amino Acid Sequence |
49 | Influenzavirus A |
47 | Influenza A virus (classification) |
47 | Antibodies, Viral (blood) |
46 | Influenza A Virus, H1N1 Subtype (immunology) |
45 | Influenza A Virus, H3N2 Subtype |
44 | Vaccination |
44 | Neuraminidase (genetics) |
43 | Neuraminidase (immunology) |
43 | Influenza A virus (isolation & purification) |
41 | Dogs |
41 | Child, Preschool |
40 | Orthomyxoviridae Infections (prevention & control) |
40 | Base Sequence |
40 | Antibodies, Viral (immunology) |
39 | Reassortant Viruses (genetics) |
38 | Influenza Vaccines (genetics) |
38 | Influenza A virus (physiology) |
37 | Influenza in Birds (virology) |
37 | Birds |
36 | Disease Outbreaks |
36 | Antibodies, Viral (analysis) |
34 | Hemagglutinin Glycoproteins, Influenza Virus (genetics) |
34 | Cross Reactions |
33 | Orthomyxoviridae (immunology) |
33 | Infant |
33 | Antigens, Viral (immunology) |
33 | Aged |
32 | Temperature |
32 | Influenza virus |
32 | Influenza A |
32 | Influenza A virus (enzymology) |
32 | Hemagglutinins, Viral (immunology) |
31 | Pandemics |
31 | Orthomyxoviridae Infections (virology) |
31 | Influenza, Human (transmission) |
31 | Influenza A virus (drug effects) |
31 | Antiviral Agents (pharmacology) |
30 | Reassortant Viruses (immunology) |
30 | Phylogeny |
30 | Influenza A Virus, H1N1 Subtype (genetics) |
30 | Antigens, Viral (analysis) |
29 | Vaccines, Attenuated (genetics) |
29 | Vaccine |
29 | RNA, Viral (genetics) |
29 | Influenza Vaccines (adverse effects) |
29 | Human |
29 | Ferrets |
28 | Influenza A Virus, H1N1 Subtype |
27 | Phenotype |
27 | Influenza A Virus, H3N2 Subtype (genetics) |
27 | Hemagglutinin Glycoproteins, Influenza Virus (immunology) |
26 | Swine |
26 | Neutralization Tests |
26 | History, 20th Century |
26 | Antiviral |
26 | Antibodies, Viral (biosynthesis) |
25 | Virulence |
25 | Influenza, Human (history) |
25 | Influenza A virus (growth & development) |
24 | Vaccines, Attenuated (administration & dosage) |
24 | Influenza A Virus, H5N1 Subtype (immunology) |
24 | Influenza A Virus, H3N2 Subtype (immunology) |
24 | Epidemiology |
23 | Time Factors |
23 | Models, Molecular |
23 | Immunization |
23 | Chickens |
22 | T-Lymphocytes, Cytotoxic (immunology) |
22 | Mouse |
22 | Influenza, Human (mortality) |
22 | Influenza A Virus, H2N2 Subtype (pathogenicity) |
22 | Cells, Cultured |
22 | Antiviral Agents (therapeutic use) |
22 | Adaptation, Physiological |
21 | Hemagglutinins, Viral (analysis) |
21 | Hemagglutinin Glycoproteins, Influenza Virus (metabolism) |
21 | Hemagglutinin Glycoproteins, Influenza Virus (chemistry) |
20 | influenza virus |
20 | Young Adult |
20 | RNA, Viral (analysis) |
20 | Influenza A Virus, H5N1 Subtype (genetics) |
20 | Hemagglutinins, Viral (genetics) |
20 | Hemagglutinin |
20 | Disease Models, Animal |
19 | Virus Replication (drug effects) |
19 | Species Specificity |
19 | Influenza, Human (microbiology) |
19 | Influenza Vaccines |
19 | Influenza B virus (immunology) |
19 | Influenza A Virus, H2N2 Subtype (isolation & purification) |
19 | Attenuated strain |
19 | Antibodies, Monoclonal (immunology) |
18 | Seasons |
18 | Neuraminidase (metabolism) |
18 | Administration, Intranasal |
17 | Viral Proteins (analysis) |
17 | Viral Matrix Proteins (genetics) |
17 | Orthomyxoviridae Infections (pathology) |
17 | Neuraminidase (antagonists & inhibitors) |
17 | Lung (virology) |
17 | Influenzavirus |
17 | Influenza A virus (analysis) |
17 | Epitopes (immunology) |
17 | Amino Acid Substitution |
16 | influenza |
16 | Vaccines, Attenuated |
16 | Russia |
16 | Protein Binding |
16 | Genotype |
16 | Epitopes |
16 | Electrophoresis, Polyacrylamide Gel |
16 | Avian influenza |
16 | Antigens, Viral (genetics) |
15 | Viral Proteins (metabolism) |
15 | Viral Plaque Assay |
15 | Vaccines, Attenuated (adverse effects) |
15 | Pandemic |
15 | Influenza in Birds (epidemiology) |
15 | Influenza A Virus, H2N2 Subtype (physiology) |
15 | Genome, Viral |
14 | Viral Proteins (immunology) |
14 | Structure-Activity Relationship |
14 | Lymphocyte Activation |
14 | Lung (microbiology) |
14 | Influenza, Human (drug therapy) |
14 | Influenza, Human (diagnosis) |
14 | Influenza A virus (metabolism) |
14 | H1N1 |
14 | Genetic Variation |
14 | Evolution, Molecular |
14 | Antibody |
14 | Antibodies, Neutralizing (immunology) |
13 | Virus |
13 | Orthomyxoviridae Infections (drug therapy) |
13 | Influenza in Birds (transmission) |
13 | Infection |
13 | Disease Outbreaks (prevention & control) |
13 | Disease Outbreaks (history) |
13 | Cricetinae |
13 | Binding Sites |
12 | influenza A virus |
12 | Zoonoses (virology) |
12 | Sequence Analysis, DNA |
12 | Rabbits |
12 | Protein Conformation |
12 | Orthomyxoviridae (genetics) |
12 | Neuraminidase (chemistry) |
12 | Microbial Sensitivity Tests |
12 | Influenza A Virus, H2N2 Subtype (chemistry) |
12 | Infant, Newborn |
12 | Hemagglutinin Glycoproteins, Influenza Virus |
12 | H5N1 |
12 | Genetic reassortment |
12 | CD8-Positive T-Lymphocytes (immunology) |
12 | Antibody Specificity |
11 | Vaccines, Inactivated (immunology) |
11 | T-Lymphocytes (immunology) |
11 | Sequence Alignment |
11 | Sensitivity and Specificity |
11 | Orthomyxoviridae Infections (mortality) |
11 | Neuraminidase |
11 | Mice, Inbred C57BL |
11 | Influenza, Human (genetics) |
11 | Influenza in Birds (prevention & control) |
11 | Influenza A Virus, H5N1 Subtype (pathogenicity) |
11 | Influenza A Virus, H2N2 Subtype (metabolism) |
11 | In vitro |
11 | Hydrogen-Ion Concentration |
11 | Hemagglutinins, Viral |
11 | CD4-Positive T-Lymphocytes (immunology) |
11 | Antiviral Agents (chemistry) |
11 | Antigens, Viral |
11 | Antibodies, Monoclonal |
10 | Zoonoses (epidemiology) |
10 | Viral Proteins (chemistry) |
10 | Vaccines, Synthetic (immunology) |
10 | RNA Replicase (genetics) |
10 | Peptides (analysis) |
10 | Orthomyxoviridae Infections (veterinary) |
10 | Nucleoproteins (genetics) |
10 | Nucleic Acid Hybridization |
10 | Mutation, Missense |
10 | Models, Biological |
10 | Mice, Inbred Strains |
10 | Mice, Inbred CBA |
10 | Lung (pathology) |
10 | Influenza B virus (drug effects) |
10 | Influenza A Virus, H5N1 Subtype |
10 | Influenza A Virus, H1N1 Subtype (physiology) |
10 | Influenza A Virus, H1N1 Subtype (pathogenicity) |
10 | Immunogenicity |
10 | Immunoenzyme Techniques |
10 | Dose-Response Relationship, Drug |
10 | B-Lymphocytes (immunology) |
10 | Avian influenzavirus |
10 | Avian influenza virus |
10 | Adamantane (analogs & derivatives) |
9 | United States (epidemiology) |
9 | Transfection |
9 | Swine (virology) |
9 | Reverse Transcriptase Polymerase Chain Reaction |
9 | Receptors, Virus (metabolism) |
9 | Prevalence |
9 | Orthomyxoviridae Infections (microbiology) |
9 | Neuraminidase (analysis) |
9 | Lung (immunology) |
9 | Kinetics |
9 | Influenza in Birds (immunology) |
9 | Influenza Vaccines (therapeutic use) |
9 | Influenza B virus (genetics) |
9 | Influenza A virus (chemistry) |
9 | Influenza A Virus, H2N2 Subtype (drug effects) |
9 | Global Health |
9 | Enzyme-Linked Immunosorbent Assay |
9 | Chlorocebus aethiops |
9 | China |
9 | Chemical synthesis |
9 | Antibody Formation |
9 | Aged, 80 and over |
9 | Age Factors |
9 | Adaptation, Biological |
8 | neuraminidase |
8 | Virology |
8 | Viral disease |
8 | Viral Matrix Proteins (immunology) |
8 | Structure activity relation |
8 | Seroepidemiologic Studies |
8 | Sequence Homology, Amino Acid |
8 | Risk Factors |
8 | Pregnancy |
8 | Peptides (immunology) |
8 | Orthomyxoviridae (enzymology) |
8 | Japan |
8 | Influenza, Human (blood) |
8 | Influenza Vaccines (isolation & purification) |
8 | Influenza A Virus |
8 | Influenza A Virus, H5N2 Subtype (immunology) |
8 | Influenza A Virus, H5N1 Subtype (isolation & purification) |
8 | Influenza A Virus, H3N2 Subtype (metabolism) |
8 | Influenza A Virus, H3N2 Subtype (chemistry) |
8 | Gene |
8 | Europe |
8 | Epitopes (analysis) |
8 | DNA, Viral (genetics) |
8 | Cross Reactions (immunology) |
8 | Cross Protection |
8 | Cold |
8 | Chickens (immunology) |
8 | Birds (virology) |
8 | Biological Evolution |
8 | Adaptation |
7 | evolution |
7 | Zoonoses (transmission) |
7 | Virus Shedding |
7 | Viral Nonstructural Proteins (genetics) |
7 | Treatment |
7 | Subtype |
7 | Reassortant Viruses (physiology) |
7 | Prevention |
7 | Oseltamivir |
7 | Orthomyxoviridae (drug effects) |
7 | Mutagenesis, Site-Directed |
7 | Microbiology |
7 | Mice, Transgenic |
7 | Influenza viruses |
7 | Influenza B virus |
7 | Immunologic Memory |
7 | Immunization, Secondary |
7 | Immunity, Cellular |
7 | Immune response |
7 | Hong Kong |
7 | Hemagglutination Tests |
7 | Experimental study |
7 | Exo-α-sialidase |
7 | Epitopes (genetics) |
7 | Epidemic |
7 | Enzyme Inhibitors (pharmacology) |
7 | Drug Evaluation, Preclinical |
7 | Double-Blind Method |
7 | Cytotoxicity |
7 | Cytotoxicity, Immunologic |
7 | Culture Techniques |
7 | Crystallography, X-Ray |
7 | Computer Simulation |
7 | Computational Biology |
7 | Comparative study |
7 | Chickens (virology) |
7 | Aves |
7 | Antiviral Agents (chemical synthesis) |
7 | Antibodies, Neutralizing (blood) |
7 | Antibodies, Monoclonal (isolation & purification) |
7 | Animal |
7 | Age Distribution |
7 | Adsorption |
6 | Zanamivir |
6 | World Health Organization |
6 | Virus Replication (genetics) |
6 | Viral Proteins (classification) |
6 | Viral Proteins (biosynthesis) |
6 | Viral Matrix Proteins (metabolism) |
6 | Vaccine strain |
6 | Vaccination (methods) |
6 | T-Lymphocyte |
6 | Survival Analysis |
6 | Surveillance |
6 | Strain |
6 | Severity of Illness Index |
6 | Reassortment |
6 | Reassortant Viruses (pathogenicity) |
6 | Population Surveillance |
6 | Pathogenicity |
6 | Pandemics (prevention & control) |
6 | Oseltamivir (pharmacology) |
6 | Orthomyxoviridae (physiology) |
6 | Orthomyxoviridae (pathogenicity) |
6 | Monoclonal antibody |
6 | Molecular Structure |
6 | Lymphocytes (immunology) |
6 | Interferon-gamma (biosynthesis) |
6 | Influenza Vaccines (pharmacology) |
6 | Influenza A Virus, H9N2 Subtype (immunology) |
6 | Influenza A Virus, H7N9 Subtype (immunology) |
6 | Influenza A Virus, H5N2 Subtype (genetics) |
6 | Influenza A Virus, H5N1 Subtype (physiology) |
6 | Influenza A Virus, H3N2 Subtype (pathogenicity) |
6 | Influenza A Virus, H2N2 Subtype (growth & development) |
6 | Influenza A Virus, H2N2 Subtype (enzymology) |
6 | Influenza A Virus, H1N1 Subtype (drug effects) |
6 | Incidence |
6 | Histocompatibility Antigens Class I (immunology) |
6 | H9N2 |
6 | H1N1 Subtype |
6 | Genes, Viral (genetics) |
6 | France |
6 | Epitopes, T-Lymphocyte (immunology) |
6 | Ducks (virology) |
6 | Ducks (microbiology) |
6 | Drug Resistance, Viral |
6 | Detection |
6 | Dendritic Cells (immunology) |
6 | DNA, Viral |
6 | Birds (microbiology) |
6 | Biological activity |
6 | Antibodies, Viral (isolation & purification) |
6 | Adaptation, Physiological (genetics) |
5 | Viral Load |
5 | Vaccines, Synthetic (genetics) |
5 | Vaccines, Attenuated (isolation & purification) |
5 | Urban Population |
5 | Treatment Outcome |
5 | Theoretical study |
5 | Survival Rate |
5 | Stability |
5 | Serial Passage |
5 | Rimantadine (pharmacology) |
5 | Replication |
5 | Reassortant Viruses (isolation & purification) |
5 | Rats |
5 | RNA, Messenger (genetics) |
5 | Polymerase Chain Reaction (methods) |
5 | Pneumonia |
5 | Plasmids |
5 | Orthomyxoviridae |
5 | Orthomyxoviridae Infections (transmission) |
5 | Orthomyxoviridae (growth & development) |
5 | Orthomyxoviridae (classification) |
5 | Neuraminidase (isolation & purification) |
5 | Molecular epidemiology |
5 | Mice, Inbred C3H |
5 | Mechanism of action |
5 | Madin Darby Canine Kidney Cells |
5 | Lymph Nodes (immunology) |
5 | Kidney |
5 | Influenza, Human (metabolism) |
5 | Influenza B virus (physiology) |
5 | Influenza A Virus, H9N2 Subtype |
5 | Influenza A Virus, H3N2 Subtype (isolation & purification) |
5 | Influenza A Virus, H1N1 Subtype (enzymology) |
5 | Influenza A Virus, H1N1 Subtype (chemistry) |
5 | Immunization Schedule |
5 | Immunity |
5 | Hong Kong (epidemiology) |
5 | Hemagglutinins, Viral (chemistry) |
5 | Hemagglutinins (genetics) |
5 | Hemagglutination, Viral |
5 | H3N2 |
5 | H1N1 influenza |
5 | Guinea Pigs |
5 | Ferrets (immunology) |
5 | Evaluation Studies as Topic |
5 | Ducks |
5 | Drug Resistance, Microbial |
5 | Disease Reservoirs |
5 | Conserved Sequence |
5 | Clinical Trials as Topic |
5 | Cell Movement (immunology) |
5 | Asia |
5 | Antigenic determinant |
5 | Antigenic Variation |
5 | Antigen |
5 | Antibodies, Viral |
5 | Amantadine (therapeutic use) |
5 | Amantadine (pharmacology) |
4 | vaccine |
4 | Zoonoses |
4 | Virus Cultivation |
4 | Viral Vaccines (immunology) |
4 | Viral Matrix Proteins (chemistry) |
4 | Viral Core Proteins (genetics) |
4 | Vaccines |
4 | Vaccines, Synthetic (administration & dosage) |
4 | Vaccines, Inactivated (administration & dosage) |
4 | United States |
4 | USSR |
4 | Tricyclic compound |
4 | Transmission |
4 | Toxicity |
4 | Swine Diseases (virology) |
4 | Swine (microbiology) |
4 | Stochastic Processes |
4 | Saturated compound |
4 | Risk Assessment |
4 | Rimantadine |
4 | Reverse Genetics |
4 | Respiratory disease |
4 | Recombination |
4 | Recombinant Proteins |
4 | Receptors, Virus (chemistry) |
4 | Reassortant Viruses |
4 | Reassortant Viruses (growth & development) |
4 | Radioimmunoassay |
4 | RNA Replicase (metabolism) |
4 | Poultry |
4 | Poultry Diseases (virology) |
4 | Polysaccharides (metabolism) |
4 | Polymerase chain reaction |
4 | Polymerase Chain Reaction |
4 | Pneumonia, Viral (pathology) |
4 | Phylogenetic analysis |
4 | Pathogenesis |
4 | Pandemics (history) |
4 | Orthomyxoviridae Infections (epidemiology) |
4 | Orthomyxoviridae Infections (blood) |
4 | Orthomyxoviridae (metabolism) |
4 | Orthomyxoviridae (analysis) |
4 | Nucleoproteins (immunology) |
4 | North America |
4 | Nitrogen heterocycle |
4 | Mutation (genetics) |
4 | Molecular evolution |
4 | Molecular Dynamics Simulation |
4 | Modeling |
4 | Mesocricetus |
4 | Medicinal plant |
4 | Macaca mulatta |
4 | Influenza, Human (pathology) |
4 | Influenza, Human (complications) |
4 | Influenza A virus (radiation effects) |
4 | Influenza A Virus, H2N2 Subtype (classification) |
4 | In Vitro Techniques |
4 | Immunoprotection |
4 | Immunoglobulin G (blood) |
4 | Immunoglobulin G (analysis) |